| SGLT2抑制剂坎格列净的临床应用研究进展 |
| |
| 引用本文： | 张帅,刘晓亮,房舒舒,曹国颖. SGLT2抑制剂坎格列净的临床应用研究进展[J]. 中国医院药学杂志, 2016, 36(5): 412-417. DOI: 10.13286/j.cnki.chinhosppharmacyj.2016.05.20 |
| |
| 作者姓名： | 张帅 刘晓亮 房舒舒 曹国颖 |
| |
| 作者单位： | 1. 北京医院药学部, 北京 100730;2. 北京大学药学院药事管理与临床药学系, 北京 100191 |
| |
| 摘 要： | 坎格列净是一种钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂, 通过阻断肾脏对葡萄糖的重吸收及增加尿液中葡萄糖的排泄, 降低血糖。多个临床研究证明其可以有效控制2型糖尿病患者的血糖, 改善患者HbA1c水平, 同时可降低患者体质量及收缩压。坎格列净不良反应主要有尿路感染、生殖道霉菌感染等, 单药使用较少出现低血糖反应, 患者对其有较好的耐受性。本文对坎格列净治疗2型糖尿病的机制、药效学、药动学、有效性和安全性等方面的研究进展进行了综述。
|
| 关 键 词： | 坎格列净 2型糖尿病 有效性 安全性 |
| 收稿时间： | 2015-08-06 |
Clinical research progress of SGLT2 inhibitor canagliflozin |
| |
| ZHANG Shuai;LIU Xiao-liang;FANG Shu-shu;CAO Guo-ying. Clinical research progress of SGLT2 inhibitor canagliflozin[J]. Chinese Journal of Hospital Pharmacy, 2016, 36(5): 412-417. DOI: 10.13286/j.cnki.chinhosppharmacyj.2016.05.20 |
| |
| Authors: | ZHANG Shuai LIU Xiao-liang FANG Shu-shu CAO Guo-ying |
| |
| Affiliation: | 1. Department of Pharmacy, Beijing Hospital, Beijing 100730, China;2. Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China |
| |
| Abstract: | Canagliflozin is an inhibitor of sodium-glucose co-transporter-2. It can reduce glucose reabsorption in proximal tubules and increase urinary glucose excretion, resulting in decreased plasma glucose. Canagliflozin is effective in reducing glucose levels in patients with type 2 diabetes. It also can reduce body weight and systolic blood pressure. Main adverse effects of canagliflozin include urinary tract infections and genital mycotic infections. Risk of hypoglycemia is low during canagliflozin monotherapy. This paper summarizes mechanism, pharmacodynamics, pharmacokinetics, efficacy and safety of canagliflozin in treatment of type 2 diabetes. |
| |
| Keywords: | canagliflozin type 2 diabetes efficacy safety |
| 本文献已被 CNKI 等数据库收录！ |
| 点击此处可从《中国医院药学杂志》浏览原始摘要信息 |
|
点击此处可从《中国医院药学杂志》下载全文 |
|
